Jakafi Price (ruxolitinib)

Jakafi price by strength

Cheapest ways to get Jakafi 10 mg

The cheapest ways we found to get brand Jakafi 10 mg (prices checked Nov 11, 2026). The lowest 90-day cost is shaded green.

Costs abroad and at U.S. pharmacies are for one order closest to 90 days, shipping included, from the price table above. Programs set their own rules, so check the terms before you count on one.

How much does Jakafi cost without insurance?

Without insurance, Jakafi costs $18,190 for a 30-day supply at the U.S. list price, or about $54,570 for 90 days. Licensed pharmacies abroad charged from $19,074.59 for 90 days of brand Jakafi 10 mg in our latest check (Nov 11, 2026), shipping included. Incytecares free medicine: Free Jakafi for eligible patients who are uninsured or underinsured. Call IncyteCARES at 1-855-452-5234 (Incyte).

Jakafi cost with Medicare

In 2026, a Medicare drug plan (Part D) can charge a deductible of up to $615, and once you've spent $2,100 out of pocket on covered drugs, you pay nothing more for covered drugs that year ($2,400 in 2027) (Medicare.gov). What you pay for Jakafi depends on your plan's drug list and your coverage phase. If your income is limited, Extra Help lowers drug costs: in 2026 you pay no more than $5.10 for a generic and $12.65 for a brand-name drug, with income under $23,940 ($32,460 for a married couple) and resources under $18,090 ($36,100 for a couple) (CMS). The free Medicare Prescription Payment Plan spreads costs into monthly payments, but it doesn't lower the total.

Jakafi cost with insurance

With private or employer insurance, what you pay for Jakafi depends on your plan's drug list, deductible and copay. As little as $0 a month with the IncyteCARES copay program, subject to an annual benefit maximum. Your copay otherwise depends on your plan (Incyte).

Medicaid: Your state Medicaid program sets any copay. Ask your pharmacist or state Medicaid office (Medicaid.gov).

Jakafi patient assistance program

Yes. Jakafi is offered through IncyteCARES Patient Assistance Program, which can give the medicine at no cost to people who qualify. Who qualifies: Patients who are uninsured or underinsured for Jakafi. Terms apply and can change. How to apply: For Jakafi, call IncyteCARES at 1-855-452-5234 or ask your prescriber to enroll you. For Opzelura, start at incytecares.com (Opzelura support page). (Checked 2026-10-29.)

Jakafi FAQ

Savings programs from the maker

eDrugSearch does not offer its own Jakafi coupons. Incyte's patient support program for Jakafi is IncyteCARES (1-855-452-5234). Each program below lists who it is for.

• IncyteCARES copay program: for people with commercial prescription drug coverage. Eligible patients may pay as little as $0 a month, subject to an annual benefit maximum. Not for uninsured or cash-paying patients, or for Medicare Part D, Medicare Advantage, Medicaid, TRICARE or state assistance programs. Copay maximizer or accumulator programs may reduce its value. Call 1-855-452-5234. (IncyteCARES for Jakafi)
• IncyteCARES Patient Assistance Program (free medicine): Incyte may provide Jakafi at no cost to eligible patients who are uninsured or underinsured, including people with Medicare Part D who can't afford it. Terms and conditions apply and may change; contact IncyteCARES to check eligibility. (IncyteCARES for Jakafi)
• Medicare Extra Help: if you have Medicare and limited income, Extra Help may lower your Jakafi copay to $0 to $12.65 per prescription in 2026. (Social Security)
• Medicare Prescription Payment Plan: a free Medicare option that spreads your drug costs into monthly payments across the year. It doesn't lower the total, but it can make costs easier to manage. (Medicare.gov)

What is Jakafi used for?

Jakafi (ruxolitinib) is a kinase inhibitor, also called a JAK inhibitor. According to its FDA label (prescribing information), it is used to treat:

• Intermediate- or high-risk myelofibrosis in adults, including primary myelofibrosis and myelofibrosis that follows polycythemia vera or essential thrombocythemia.
• Polycythemia vera in adults who did not respond well enough to, or could not tolerate, hydroxyurea.
• Acute graft-versus-host disease (GVHD) that did not respond to steroids, in adults and children 12 years and older.
• Chronic GVHD after one or two other systemic treatments did not work, in adults and children 12 years and older.

Jakafi comes as 5, 10, 15, 20 and 25 mg tablets in bottles of 60 and is usually taken twice a day. It has no boxed warning. The label warns about low blood counts, serious infections, symptoms coming back after treatment is interrupted or stopped, non-melanoma skin cancer, higher cholesterol, heart attack and stroke, blood clots and new cancers. Your prescriber decides which medicine is right for you.